Irish pharmaceutical firm Mallinckrodt has completed the approximately $1.4bn acquisition of US-based biopharmaceutical company Cadence.

Cadence is best known for its pain drug Ofirmev (acetaminophen injection), a proprietary intravenous formulation of acetaminophen. The drug is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever.

The acquisition is expected to be immediately accretive to Mallinckrodt’s fiscal year 2014 adjusted diluted earnings per share, as well as significantly accretive to its fiscal year 2015 adjusted diluted earnings per share. It adds Ofirmev to Mallinckrodt’s growing roster of brands and strengthens its speciality drugs portfolio in addition to expanding the company’s presence in the US hospital market.

Mallinckrodt president and chief executive officer Mark Trudeau said that Ofirmev will significantly expand the company’s ability to serve US hospitals.

"As anticipated, the transaction was straightforward, closed quickly, and we are planning for a rapid and successful integration which we expect to be completed by the beginning of September," Trudeau said.

"We believe this accelerated integration will provide greater clarity and direction for the employees joining us, and ensure that the merger of Ofirmev and the transition of the hospital team into Mallinckrodt is smooth and best serves our customers."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company said that the effectiveness of Ofirmev for the treatment of post-surgical acute pain and fever has not yet been studied in paediatric patients less than two years of age.